Skip to main navigation Skip to search Skip to main content

N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells

  • Patrick M. Long
  • , John R. Moffett
  • , Aryan M.A. Namboodiri
  • , Mariano S. Viapiano
  • , Sean E. Lawler
  • , Diane M. Jaworski*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Background: N-acetylaspartate (NAA), the primary source of brain acetate, and aspartoacylase (ASPA), the enzyme that catabolizes NAA, are decreased in glioma, thereby decreasing acetate bioavailability. Results: Treatment with NAA and NAAG promotes growth and inhibits differentiation of glioma stem-like cells (GSCs). Conclusion: This study links acetate bioavailability and GSC malignancy. Significance: Because NAA/NAAG-mediated acetate supplementation promoted GSC growth, an alternative acetate therapeutic is required.

Original languageEnglish
Pages (from-to)26188-26200
Number of pages13
JournalJournal of Biological Chemistry
Volume288
Issue number36
DOIs
StatePublished - 6 Sep 2013

Fingerprint

Dive into the research topics of 'N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells'. Together they form a unique fingerprint.

Cite this